STUDresearch · Non-peptide
ERR agonist class (SLU-PP family)
Also known as
SLU-PP-332 · SLU-PP-915 · SLU-PP class · SLU PP class · ERR agonists · ERR pan-agonists · pan-ERR agonists · exercise mimetic discussion class · Saint Louis University PP series · Burris lab ERR agonists
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Lots of talk
Systemic
Oral / SubQ
Metabolic research compounds
Systemic — small-molecule pan-ERR agonists studied for body-wide aerobic gene programs, energy use and exercise adaptation.
What people say
The SLU-PP class consists of small-molecule pan-ERR agonists led by SLU-PP-332 and chemically distinct SLU-PP-915. The preclinical program studies exercise-linked transcription and metabolism; neither compound has a published human efficacy or Phase 1 package.
Doses people talk about
Rows preserve molecule, species and route. Animal amounts are not human protocols, and inspected community amounts came from unverified products with no controlled dose finding.
How it may feel
Human same-day experience is inconsistent. Inspected 915 reports ranged from endurance or focus with later fatigue to no established acute pattern, while much of the warmth and flush language belongs to 332 use. Molecule, route and stacks must remain explicit.
Inspected SLU-PP-915 reports20 mg once daily or 30 mg twice daily
Separate anonymous oral reports with unverified products; one combined 20 mg daily with BAM15.
SLU-PP-332 mouse efficacy25–50 mg/kg IP, often twice daily
Model-specific mouse regimens lasting days to weeks; not an oral or human range.
SLU-PP-332 mouse exposure sample30 mg/kg IP once
Plasma and muscle were sampled at two and six hours; this does not establish half-life.
SLU-PP-915 mouse study range0.2–32 mg/kg oral or IP
Once- or twice-daily mouse experiments for up to seven days; not human dosing.
Half-life & effect duration
- Half-life in the body
- SLU-PP-915 · oral · miceAbout 18–28 minutes
- SLU-PP-332 · community timing claimsAbout 1–2 hours, 3–6 hours or 12–16 hours; sources conflict
- SLU-PP-915 · liver-cell stability testOver 60 minutes
- Felt duration people report
- Injected 332 community reportsWarmth or flushing within about 20–60 minutes
- Other reports across the two compoundsEndurance, focus, fatigue or no effect; duration varies
Cycles people discuss
Two-to-eight-week self-experiments are community convention, not class-wide human science. Published mouse windows vary by compound, route and model and cannot validate an on/off calendar.
Timing
Community notes favor morning or pre-activity use, sometimes split 2–3 times daily between morning and afternoon; late use is blamed for night sweats or restless sleep. Oral 332, injectable 332 and oral 915 remain distinct discussions, not interchangeable schedules or a validated class regimen.
Stacks
Solo experiments preserve more attribution. Pairing SLU compounds with 5-Amino-1MQ, MOTS-c or other metabolic agents, or switching compounds after a null run, makes class and product effects difficult to distinguish.
Watch for
Unknown human safety (class): No large controlled chronic AE datasets or Phase 1 packages for gray-market 332 or 915. Long-term cardiac, hepatic, endocrine, and oncologic risk of chronic pan-ERR agonism is open.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
Oral SLU-PP-915 plasma half-life was 18–28 minutes in mice.
Billon et al. measured oral concentration-time profiles at 2, 8 and 32 mg/kg and compared acute with repeated exposure.
This applies to study compound in male mice, not SLU-PP-332, humans or gray-market material.
- Billon et al. — An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (opens in a new tab)Primary SLU-PP-915 mouse paper reports 0.2–32 mg/kg oral or IP experiments, 18–28 minute oral plasma half-life and repeated-dose findings.Mouse study; it does not establish human PK, safety or a shared class schedule.
Half-life in the body
No class-wide or exact-compound human parent-plasma half-life was established.
The reviewed 332 paper supplies two- and six-hour concentration samples after mouse IP dosing; the reviewed 915 paper supplies mouse oral PK only.
Vendor and forum durations cannot substitute for human pharmacokinetic analysis, and the two molecules cannot share one value.
- Billon et al. — Synthetic ERR alpha/beta/gamma agonist induces an ERR alpha-dependent acute aerobic exercise response and enhances exercise capacity (opens in a new tab)Primary SLU-PP-332 mouse paper reports 30 mg/kg IP exposure sampling at two and six hours and 25–50 mg/kg IP efficacy regimens.Mouse IP work on 332; sampling times are not a terminal half-life and cannot be transferred to 915 or humans.
- Billon et al. — An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (opens in a new tab)Primary SLU-PP-915 mouse paper reports 0.2–32 mg/kg oral or IP experiments, 18–28 minute oral plasma half-life and repeated-dose findings.Mouse study; it does not establish human PK, safety or a shared class schedule.
Felt duration people report
No dependable class-wide felt-duration pattern emerges from the inspected human discussion.
Reported warmth, endurance, focus, fatigue and null experiences vary by 332 versus 915, oral versus injected route, amount and stacks.
Anonymous self-reports with unverified products and multiple co-interventions cannot establish causality, prevalence or transfer between compounds.
- Reddit r/SLUPP332 — Slu-pp-915 (opens in a new tab)Multiple authors distinguish 332 and 915, discuss oral 915 availability and report conflicting 20 mg daily plus BAM15 and 30 mg twice-daily experiences.Anonymous unverified products and multi-agent use; no controlled comparison or reliable class attribution.
- Reddit r/Biohackers — 20MG SLU-PP-915 Experiment (opens in a new tab)Deleted-author thread retains identity doubts and opposing 2 mg, 20 mg and higher dose opinions, illustrating the class's route and amount confusion.Original post deleted; conflicting comments, no assay confirmation and invalid mouse-to-human extrapolations.
Other context in this card
- Hampton et al. — Development and pharmacological evaluation of a new chemical series of potent pan-ERR agonists, identification of SLU-PP-915 (opens in a new tab)Primary medicinal-chemistry and mouse study identifies SLU-PP-915 and reports target-gene and exercise experiments.Cell and mouse work only; it does not provide class-wide or human dosing.
What people say
- Community inject 332 logs: Easier cardio at familiar workloads, warmth/sweat, modest fat-loss assist under deficit — highly confounded by diet, training, and stacks. forumanecdote
- Community oral 332 logs: Hard split — many nulls at 250–500 mcg capsules vs “energy / peel” claims at multi-mg to tens-or-hundreds-of-mg oral talk. Oral F is the explanatory fight, not just “responder genetics.” forum
- Community 915 oral talk: Framed as fewer pure “dead capsule” outcomes if identity is real; still thin verified multi-month human logs vs older agents. forum
- What mice do not prove for bros: Human VO2 PRs, scale-only fat loss without deficit, or sedentary “replaces the gym” outcomes are not established. trialforum
- Endurance (mice, 332): ACS Chem Biol 2023-line work — treated mice ran substantially longer/farther (community/secondary summaries often cite ~70% longer time and ~45% farther distance) with shift toward type IIa oxidative fibers. animal
- Endurance (mice, 915): Oral/IP 915 work reports exercise-capacity gains comparable to 332 in several setups; secondary summaries often cite ~50% improvements in running distance/time vs vehicle — animal only. animal
- Fat mass / weight (obese mice, 332): Multi-week IP dosing reduced fat gain vs vehicle on high-fat diet without reducing food intake; media/secondary summaries of DIO work often cite ~10× less fat gain and ~12% body-weight reduction over ~1 month. animal
- Fuel shift: Lower RER (more fat oxidation) and higher calculated fatty-acid oxidation in mouse metabolic cages after 332. animal
- Energy expenditure: Higher resting/whole-body energy burn without more spontaneous activity in metabolic-syndrome mouse models. animal
- Glucose / lipids (mice): Improved glucose tolerance, insulin-related signals, triglycerides, and hepatic fat endpoints in DIO and ob/ob 332 regimens (~12–28 days IP BID in published protocols). animal
- Acute gene program (both): Muscle ERR targets including PGC-1α, PDK4, LDHA, DDIT4/Ddit4 rise within ~1 hour of research IP doses; Ddit4 can match or exceed a treadmill bout depending on muscle and compound. animal
- Mitochondrial signals (915 oral work): Higher mtDNA content and mitochondrial gene expression reported with repeated oral 915 in mouse summaries. animal
- Cardiac (disease models): Xu et al. Circulation — pan-ERR agonists 332 and 915 improved ejection fraction, reduced fibrosis, increased survival in pressure-overload HF models without reversing hypertrophy; metabolomics pointed at FAO / TCA–OXPHOS normalization. Preclinical disease model, not healthy-human green light. animal
- Kidney aging model (332): Separate mouse work (e.g. Wang-line summaries) used chronic IP 332 and reported preserved mitochondrial / podocyte markers — not a forum fat-loss endpoint. animal
Doses people talk about
- Class rule #1 — name the molecule: 332 oral culture, 332 inject culture, and 915 oral culture are three different dose conversations. Copying charts across them is the main source of “dosages are insane” confusion. forum
- Allometric noise: Naive BSA scaling of 25–50 mg/kg mouse can spit out hundreds of mg/day human-order figures (community examples include ~100–650 mg/day talk). Community injectable protocols sit far below that; high oral-mg lore tries to chase scaled exposure despite unknown oral F. Neither path is validated human PK. forum
- 332 oral retail micro-capsules: Very common SKU ~250 mcg (0.25 mg) per cap; community starts often 250–500 mcg/day, sometimes BID. Widely attacked as “placebo tier” given published oral-F problem. forumtrial
- 332 oral mid/high culture: Multi-mg daily (~1–10+ mg), ~20–100 mg “sweet spot” lore, vendor 50 mg tablets (½–2 tablets = 25–100 mg/day patterns), and outlier influencer 100–400 mg experimental runs. Huge variance; none are human trial doses. forumanecdote
- High-mg vs nanomolar-potency fight: Counter-camp argues ERRα EC50 ~98 nM (ERRβ ~230 nM, ERRγ ~430 nM in cell assays) means systemic ~0.2–1 mg may already saturate if exposure is real — so 50–100+ mg oral talk is either compensating for near-zero F or is pharmacologically wasteful. Both camps lack human PK. trialforum
- 332 community injectable (SubQ research material): Commonly 250–500 mcg/day start; typical cluster ~500 mcg–1.5 mg/day; some protocols 1.25–2.5 mg/day; split BID/TID (e.g. 250 mcg ×2–4). Far below mouse-scaled mg totals. forum
- Split dosing habit: BID (sometimes TID) mirrors short mouse coverage and short circulating half-life claims; morning + afternoon or morning + pre-activity is common. Late big doses more often blamed for sleep hit. forumanimal
- 5 on / 2 off: Appears in some oral-protocol blogs for 332; not literature-derived. forum
- Route hierarchy in serious threads: Published mouse IP → experimental human SubQ 332 → oral 915 (intended oral story) → oral 332 capsules (most disputed) → sublingual liquids (marketed gut-bypass; no published F). trialforum
- Identity before mg: Underfilled caps, wrong molecule, OEM skepticism (especially early 915 supply talk), and unit confusion (mcg vs mg tablets that differ by 100×) make dose comparisons almost meaningless without assay. forum
- Do not dual-ERR load: Stacking 332+915 same cycle for “more ERR” is speculative overkill in community risk talk. forum
- 915 community oral: Emerging multi-mg capsule culture; openly discussed ~20 mg/day capsule experiments; some call 2 mg already high, others float ~100 mg tablet goals from scaled mouse exposure. Influencer claim: 915 oral doses often lower than high-oral-332 culture because of better oral F — marketing-adjacent, not a trial label. forum
- Framing: All human figures are research-chem / forum / influencer discussion or naive allometry — not clinical dosing, not medical advice, not for consumption. Mouse mg/kg is not a human protocol. forumtrial
- Mouse 332 efficacy (primary literature): Roughly 25–50 mg/kg intraperitoneal, often twice daily (BID), for ~12–28 days depending on model (endurance, DIO, ob/ob). Billon ACS Chem Biol / J Biol Chem line; metabolic work commonly discussed as 50 mg/kg IP BID. animaltrial
- Mouse 332 acute / PK sampling: Exposure work often cites ~30 mg/kg IP single dose with plasma and muscle still measurable at ~2–6 h (muscle > plasma in some summaries). animal
- Mouse 915: Discovery/acute work summarized at ~20 mg/kg IP for gene induction and treadmill capacity; oral paper dose-ranging often summarized across roughly ~0.2–32 mg/kg oral or IP. Authors report comparable performance to 332 at lower relative doses in some head-to-heads. animal
How it may feel
- Minutes–hours (inject 332 culture): Some SubQ users report warmth, mild flush, “primed for cardio,” or higher perceived HR within ~20–60 min; many feel nothing same day. forumanecdote
- Hours 1–6 (biology vs feel): Mouse RER / transcriptional programs move within ~1–2 h of IP; human “same-day feel” is inconsistent and is not multi-week body-comp change. animalforum
- Days 1–3: Heat, flushing, or extra sweat more common than a clear performance jump when something is felt; oral micro-capsules often completely null. forum
- Week 1: Mostly titration / side watch; gene-level changes in mice precede phenotype by days–weeks, so flat week-1 human logs are expected even if exposure is real. animalforum
- Weeks 2–4: Usual community checkpoint for “cardio easier,” sweat pattern, or scale/photos. Injectable 332 reports cluster here more than oral 332. forum
- Weeks 4–8: Longer cut/endurance experiment window; some claim steadier aerobic comfort or fat-trend continuity when deficit + training are present. Non-responders still common. forum
- If flat ~3–4 weeks on oral 332: Dominant forum hierarchy is: oral F / fake or underfilled product / no deficit / no training stimulus — before “ERR agonism does nothing.” Switching to inject 332 or to oral 915 is the recurring lore path. forumtrial
- Month 1 (mouse peak window): Published metabolic/endurance mouse endpoints often sit at ~15–28 days of high IP BID dosing — not a human guarantee timeline. animal
Cycles people discuss
- First trial block: 2–4 weeks is the common “does anything happen” experiment length for either molecule. forum
- Standard longer run: 4–8 weeks on is the modal body-comp / endurance discussion block; many cycle off around week 8 when effects plateau or product runs out. forum
- Extended: 8–12 weeks oral patterns appear; multi-month continuous human safety is not established. forum
- Time off: Informal equal off (e.g. 4–8 weeks off) or short 1–2 week breaks; no pharmacology-backed washout standard. forum
- 5 on / 2 off: Vendor-blog oral pattern for some 332 users; not from Burris papers. forum
- Failed oral 332 → try 915 (or inject 332): Recurring sequential path, not simultaneous dual pan-agonism. forumanecdote
- Continuous daily while cutting: Some open-ended use during prep; others pulse only around cardio blocks — no consensus. forum
- Restarts: Common on later cuts; re-titration science does not exist. forum
- Mouse chronic windows: Often ~12 days (ob/ob) to ~15–28 days IP BID for 332 metabolic/endurance papers; HF models multi-week; 915 oral paper includes multi-day (e.g. ~7-day) repeated oral regimens. Not human cycle science. animal
- Long-term human safety: Not established for either compound at any continuous schedule. trial
Timing
- Unverified SLU-PP-332 timing claims: Vendor and forum pages give conflicting 1–2-hour, 3–6-hour and longer coverage estimates. The reviewed primary 332 paper reports plasma and muscle concentrations at two and six hours after 30 mg/kg IP, not a human or mouse terminal half-life. forum
- Conflicting vendor timing: Occasional 12–16-hour assertions contradict shorter vendor and forum claims and were not supported by an exact-product human PK source in this review. forum
- Timing habit: Morning / pre-activity preferred; late dose more often blamed for night sweats or restless sleep. forum
- Human PK gap (class): No solid public human half-life, oral F%, SC bioavailability, Cmax, or steady-state package for gray-market 332 or 915. trial
- 332 oral problem (published): Billon oral-activity paper on 915 explicitly states parent 332 lacks oral bioavailability — root of “oral 332 = placebo” lore. trial
- 915 oral design goal: Chemically distinct scaffold with dose-dependent plasma after oral and IP administration in mouse work; oral efficacy maintained when systemic exposure is accounted for (authors). trial
- Mouse 332 exposure window: After ~30 mg/kg IP, plasma and muscle still detectable around ~2–6 h in Billon-line sampling; muscle often higher than plasma at early time points in secondary write-ups. animal
- Short practical coverage: Mouse BID regimens reflect need to maintain tissue exposure — class is not a weekly depot. animal
- 915 PK shape (secondary summaries): Rapid distribution and clearance; IP exposure > oral; repeated oral dosing summarized as no excessive accumulation over short multi-day windows. animal
- 915 microsomal stability (discovery): Boronic-acid analog (10s / 915) showed T½ > 60 min in mouse and human liver microsomes in SAR papers — in vitro only. lab
- Acute biology timing: Muscle ERR gene programs elevated by ~1 h after research IP doses; RER can shift within hours. animal
- Downstream programs: Nuclear-receptor transcriptional adaptations may outlast peak plasma — model inference, not a measured human “effect half-life.” trial
- Anti-doping metabolism: In-vitro human-liver work maps multiple Phase-I (and for 332, Phase-II) metabolites of both 332 and 915 for analytical detection. trial
More on what it is
- Why people care: 2023 mouse papers framed 332 as an “exercise mimetic” — more treadmill endurance, higher energy expenditure, less fat mass without eating less or running more. Media + research-chem commerce created the class discussion. animalforum
- Core bro differentiator (332 vs 915): Later papers state parent SLU-PP-332 lacks oral bioavailability; SLU-PP-915 was designed to be orally active with comparable exercise-mimetic activity in mice. That sentence drives the entire “oral 332 = placebo” vs “switch to 915” culture. trialforum
- What the class is not: Not cardarine (GW501516 / PPARδ), not AICAR, not caffeine, not a full training replacement, not pharmacy-compounded medicine, not estrogen HRT (ERR ≠ classic estrogen receptor therapy despite the name). forumtrial
- Trust filter: Vendor half-life tables, “cardio in a pill,” mouse-mg/kg→human tablet math, and unlabeled powder identity are the main noise sources. forum
- What the class is: Synthetic small-molecule pan-agonists of estrogen-related receptors ERRα, ERRβ, and ERRγ from the Burris lab / Saint Louis University line. Lead community names: SLU-PP-332 (first widely hyped tool) and SLU-PP-915 (chemically distinct oral follow-on). Neither is an approved drug. trial
- Mechanism (plain): ERR nuclear receptors (especially ERRα-leaning potency for 332) partner with PGC-1α-axis programs to turn up mitochondrial biogenesis, fatty-acid oxidation, OXPHOS, and aerobic exercise gene signatures (e.g. DDIT4/Ddit4). Not a classic stimulant, SARM, GLP-1, or PPARδ drug. trial
- Evidence honesty: Strong preclinical mouse package (endurance, DIO/ob/ob metabolic syndrome, some HF models). No published human RCTs / Phase 1 PK package for gray-market self-experimentation. Human “results” are anecdote + confounded stacks. trial
Stacks
- Solo experiment first: Often recommended so null vs response is not blamed on a five-agent cut stack. forum
- Top dual (332 culture): SLU-PP-332 + 5-Amino-1MQ — most-named pairing (ERR oxidative program + NNMT / NAD-adjacent metabolic talk). forum
- Triple metabolic: SLU + 5-Amino-1MQ + MOTS-c appears in synergy write-ups (mitochondrial / AMPK adjacency); attribution gets muddy fast. forum
- 332 vs 915 choice, not stack: Common plan is inject 332 or oral 915, not both. Dual pan-ERR same-day is speculative risk stacking. forum
- Failed oral 332 → 915 switch: Sequential narrative path after null oral-332 runs. anecdote
- Endurance adjacency: Cardarine (GW501516) / other “exercise mimetic” PPARδ talk sits next to ERR threads; cardarine carries its own rodent carcinogenicity / WADA history. forum
- GLP-1 era stacks: Semaglutide / tirzepatide / retatrutide for appetite deficit + SLU class for “oxidative tone / muscle fuel” theory — no published combo safety or synergy data. forum
- NAD support chatter: NMN, NR, NAD+, urolithin A sometimes listed alongside mitochondrial-leaning stacks. forum
- Cut confounds: Caffeine, yohimbine-class stims, AOD-9604, SARMs — multi-agent logs cannot isolate ERR effect. forum
- BAM15 / uncoupler talk: Occasional advanced pairing with mitochondrial uncouplers — risk stacking, not mainstream. forum
- Training is the real stack: Mouse work often pairs compound with treadmill protocols; bro content that keeps honesty still says the class does not replace progressive cardio + calorie control. animalforum
- No controlled multi-agent trials: Forum synergy claims are not safety or efficacy evidence. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Heat / flushing / excess sweat: Top human anecdote cluster when something is felt — hot flashes, facial warmth, gym sweat spikes. forumanecdote
- Sleep hit: Late dosing often blamed for night sweats or restless sleep; many keep dosing morning-only. forum
- Energy crash / biphasic feel: Wired or warm window then fatigue or “have to lie down” logs at higher experimental amounts. anecdote
- Heart rate: Elevated resting or training HR in some human logs; secondary write-ups also discuss mouse HR signals — not proven safe. animalforum
- GI upset: Occasional stomach discomfort, cramping, nausea — more often discussed with higher oral mg. anecdote
- Shakes / jitter / anxiety: Minority reports at higher experimental amounts (including low-mcg anecdotes in some sensitive users). anecdote
- Hunger paradox: Occasional higher-oral-experiment logs of increased hunger — opposite of “effortless cut” marketing. anecdote
- Oral-F false negative: Interpreting “332 capsules failed” as “ERR class does nothing” confuses absorption with mechanism — published papers say 332 lacks oral bioavailability. trialforum
- Source / purity / unit risk: Mislabeled mcg vs mg SKUs (100× errors), underfilled caps, contaminated powder, or non-915 sold as 915. Identity risk often exceeds storage risk. forum
- Estrogen-name confusion: ERR ≠ estrogen receptor HRT; uninformed “estrogen agonist” panic appears in threads, but the targets are orphan nuclear receptors. trialforum
- Not exercise replacement: “Cardio in a pill / burn fat while lazy” marketing exceeds evidence; sedentary human outcomes untested. forum
- Drug interactions: Unknown with common meds, GLP-1s, stims, or SARMs — forums are not PK studies. forum
- Dual-ERR stacking caution: 332+915 same-day multiplies unknown exposure without clear upside. forum
- Unknown human safety (class): No large controlled chronic AE datasets or Phase 1 packages for gray-market 332 or 915. Long-term cardiac, hepatic, endocrine, and oncologic risk of chronic pan-ERR agonism is open. trial
- Cardiac nuance (double-edged): Preclinical HF models showed protective signals (EF, fibrosis, survival) for 332/915 — that is not clearance for healthy humans pushing performance doses. animal
- Doping / sport: Metabolite characterization for 332 and 915 exists; performance-mimetic class is on anti-doping radar. trial
- Conflict-of-interest honesty: Much primary efficacy work is single-lineage (Burris lab) with disclosed commercial interest in ERR agonists; independent replication of key endpoints is limited. trial
- Legal / RUO status: Research chemicals / not FDA-approved for human use; jurisdiction and possession rules vary. trial
- Listen-to-body default: Community self-experimentation default is stop if cardiac-rhythm changes, persistent fatigue, severe sleep disruption, or unexplained labs appear — still not medical advice. forum
Evidence mix
Mixed trial + community tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.